Strs Ohio Has $562,000 Position in Bio-Rad Laboratories, Inc. (BIO)

Strs Ohio increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 60.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,797 shares of the medical research company’s stock after acquiring an additional 677 shares during the period. Strs Ohio’s holdings in Bio-Rad Laboratories were worth $562,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. Principal Financial Group Inc. increased its holdings in Bio-Rad Laboratories by 2.5% in the 1st quarter. Principal Financial Group Inc. now owns 88,336 shares of the medical research company’s stock valued at $22,091,000 after buying an additional 2,127 shares during the period. Xact Kapitalforvaltning AB increased its holdings in Bio-Rad Laboratories by 7.8% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 2,772 shares of the medical research company’s stock valued at $800,000 after buying an additional 200 shares during the period. Raymond James Trust N.A. bought a new position in Bio-Rad Laboratories in the 2nd quarter valued at about $212,000. Winslow Asset Management Inc. increased its holdings in Bio-Rad Laboratories by 1.2% in the 2nd quarter. Winslow Asset Management Inc. now owns 28,276 shares of the medical research company’s stock valued at $8,159,000 after buying an additional 325 shares during the period. Finally, Oakbrook Investments LLC increased its holdings in Bio-Rad Laboratories by 117.1% in the 2nd quarter. Oakbrook Investments LLC now owns 1,900 shares of the medical research company’s stock valued at $548,000 after buying an additional 1,025 shares during the period. 63.80% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have commented on BIO. Barclays decreased their target price on shares of Bio-Rad Laboratories from $345.00 to $315.00 and set an “equal weight” rating on the stock in a report on Friday, November 2nd. Jefferies Financial Group raised their price target on shares of Bio-Rad Laboratories from $325.00 to $355.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. Zacks Investment Research downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, August 13th. Morgan Stanley initiated coverage on shares of Bio-Rad Laboratories in a research note on Thursday, September 20th. They issued an “equal weight” rating and a $335.00 price target on the stock. Finally, Goldman Sachs Group initiated coverage on shares of Bio-Rad Laboratories in a research note on Wednesday, October 17th. They issued a “buy” rating and a $350.00 price target on the stock. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $338.43.

NYSE:BIO opened at $276.42 on Friday. The firm has a market capitalization of $8.45 billion, a PE ratio of 67.42, a P/E/G ratio of 3.45 and a beta of 1.07. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.49 and a quick ratio of 3.16. Bio-Rad Laboratories, Inc. has a twelve month low of $231.00 and a twelve month high of $345.15.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, November 1st. The medical research company reported $0.91 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.25). The company had revenue of $545.10 million during the quarter, compared to the consensus estimate of $541.23 million. Bio-Rad Laboratories had a net margin of 55.13% and a return on equity of 3.72%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.91 EPS. Analysts forecast that Bio-Rad Laboratories, Inc. will post 5.47 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Strs Ohio Has $562,000 Position in Bio-Rad Laboratories, Inc. (BIO)” was originally published by WKRB News and is the sole property of of WKRB News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.wkrb13.com/2018/11/10/strs-ohio-has-562000-position-in-bio-rad-laboratories-inc-bio.html.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Featured Story: How to Invest in Growth Stocks

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply